Recentstudies have demonstrated that it may be advantageous to inhibit ErbB1 andErbB2 simultaneously in those patients overexpressing the ErbB2/HER-2/neu gene,which constitutes approximately 25% of all cases of primary breast cancer [32–35]. Here, ERBB2 is linked to breast cancer.